Charles E. Rengifo

Suggest Changes
Learn More
Adequate methods to identify which lung cancer patients are most likely to benefit from the targeted drugs against both epidermal growth factor receptor/epidermal growth factor (EGFR/EGF) are needed.(More)
  • 1